4DMedical climbing back towards $2/sh on back of Stanford lung imaging tech rollout

4DMedical (ASX:4DX) has popped once again on Wednesday after demonstrating its next-generation lung imaging tech at Stanford University, pushing the much-followed stock back closer to +300% gains.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

4DX, which offers so-called “four-dimensional” lung imaging, may be forgiven that obvious faux pas by calling the company’s main prop for what it really is: Non-invasive lung scanning techniques that don’t require patients to ingest radiofluorides before imaging, per PET scans et al.

It won FDA approval for its tech just recently, and now Stanford University’s in-house medical centre has adopted the tech.

The pedigree of that institution, no doubt, is underpinning the Australian company’s rise back to a $2/sh valuation on Wednesday. (Especially when the entire XJO appears to otherwise be a sea of red.)

Also sustaining optimism is that the use of 4DX tech is expanding in Brazil, where the company operates, brushing up against AstraZeneca.

“Building on the initial rollout at Hospital Madre Teresa in Belo Horizonte, 4DMedical and AstraZeneca are rapidly expanding their Lung Health Screening Program across Brazil with the addition of five new hospitals, representing an annual volume of approximately 38,000 additional CT scans,” 4DX wrote Wednesday.

HotCopper users were, as ever, bullish on the stock – which does perhaps stand out as one of the more obviously high-conviction medical device plays available on the market at this time. (Tetratherix’s strong run this year could also be evidence that a real-world product with tangible outcomes is often better understood than app-based device players such as PainChek and BlinkLab.)

4DX last traded at $1.90/sh.

Join the discussion: See what HotCopper users are saying about 4DMedical Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.